Adaptive Biotechnologies
Translate immune genetics into clinical products by making immune sequencing a new standard of care in medicine.
Adaptive Biotechnologies SWOT Analysis
How to Use This Analysis
This analysis for Adaptive Biotechnologies was created using Alignment.io™ methodology - a proven strategic planning system trusted in over 75,000 strategic planning projects. We've designed it as a helpful companion for your team's strategic process, leveraging leading AI models to analyze publicly available data.
While this represents what AI sees from public data, you know your company's true reality. That's why we recommend using Alignment.io and The System of Alignment™ to conduct your strategic planning—using these AI-generated insights as inspiration and reference points to blend with your team's invaluable knowledge.
Powered by Leading AI Models
Industry-leading reasoning capabilities with 200K context window for comprehensive analysis
State-of-the-art multimodal intelligence with real-time market data processing and trend analysis
Advanced reasoning with comprehensive industry knowledge and strategic problem-solving capabilities
The Adaptive Biotechnologies SWOT analysis reveals a company at a critical inflection point. Its core strength lies in the powerful synthesis of its market-leading clonoSEQ product and a vast, proprietary immunomics database, creating a formidable data moat. However, this potential is counterbalanced by significant cash burn and the urgent need for a clear path to profitability. The primary opportunity is expanding into the vast solid tumor MRD market, a move essential for long-term growth. This must be executed while fending off intense competition from well-funded rivals like Natera. The strategic imperative is clear: leverage the existing leadership in hematology to fund and win the battle for solid tumors, while exercising extreme financial discipline to reassure investors and achieve sustainable operations. The next 24 months will determine if Adaptive can successfully transition from a visionary R&D engine to a profitable, market-dominating enterprise.
Translate immune genetics into clinical products by making immune sequencing a new standard of care in medicine.
Strengths
- MRD LEADERSHIP: clonoSEQ holds #1 market share in hematologic malignancies
- PHARMA INTEGRATION: Genentech partnership validates immune medicine platform
- DATA MOAT: Growing database of 25B+ immune receptors creates network effect
- REIMBURSEMENT: Secured Medicare coverage for clonoSEQ in key indications
- IP PORTFOLIO: Strong patents protect core sequencing & analysis methods
Weaknesses
- CASH BURN: Significant net losses (~$250M/yr) require disciplined spend
- SALES CYCLE: Complex sale requiring education for community oncologists
- PRODUCT FOCUS: Heavy reliance on clonoSEQ revenue; T-Detect is nascent
- PROFITABILITY: Lack of clear timeline to cash flow positive spooks investors
- OPERATING EXPENSE: High R&D and SG&A costs relative to current revenue
Opportunities
- SOLID TUMORS: Massive TAM expansion for clonoSEQ in solid tumor MRD testing
- AUTOIMMUNE: Leverage platform for diagnostics in MS, Crohn's, etc.
- DRUG DISCOVERY: Identify novel T-cell receptors for cell therapy partners
- INTERNATIONAL: Untapped markets in Europe and Asia for MRD and research
- DATA LICENSING: Monetize anonymized immunomics data for external research
Threats
- COMPETITION: Natera's Signatera gaining traction in solid tumor MRD space
- PAYER PRESSURE: Potential for reduced reimbursement rates from private payers
- CAPITAL MARKETS: Difficult funding environment for non-profitable biotech
- TECH SHIFT: New, cheaper sequencing or analysis tech could disrupt platform
- REGULATORY: Increased FDA scrutiny on LDTs could impact future products
Key Priorities
- SCALE: Aggressively drive clonoSEQ adoption in heme and solid tumors
- PROFITABILITY: Execute a clear, disciplined path to cash flow breakeven
- PLATFORM: Deepen pharma partnerships to validate and fund drug discovery
- DATA: Leverage unique immunomics data to create an undeniable AI moat
Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.
| Organization | SWOT Analysis | OKR Plan | Top 6 | Retrospective |
|---|---|---|---|---|
|
|
|
Explore specialized team insights and strategies
Adaptive Biotechnologies Market
AI-Powered Insights
Powered by leading AI models:
Gemini
- No data acquisition information available
- Founded: 2009
- Market Share: Leading share in hematologic MRD; emerging player in solid tumor MRD.
- Customer Base: Oncologists, pharmaceutical companies, academic researchers.
- Category:
- SIC Code: 2835
- NAICS Code: 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Location: Seattle, Washington
-
Zip Code:
98102
Seattle, Washington
Congressional District: WA-7 SEATTLE
- Employees: 850
Competitors
Products & Services
Distribution Channels
Adaptive Biotechnologies Business Model Analysis
AI-Powered Insights
Powered by leading AI models:
Gemini
- No data acquisition information available
Problem
- Delayed, inaccurate disease monitoring
- Ineffective, one-size-fits-all therapies
- High cost of failed drug development
Solution
- Ultra-sensitive MRD testing (clonoSEQ)
- Immune-mapping for drug discovery
- Personalized diagnostic insights
Key Metrics
- clonoSEQ test volume and revenue
- Pharma partnership revenue & milestones
- Cash burn rate and path to profitability
Unique
- Mapping T-cell/B-cell receptors at scale
- Linking immune repertoire to disease state
- The world's largest immunomics database
Advantage
- Proprietary data network effects
- FDA clearances and regulatory approvals
- Deeply embedded pharma partnerships
Channels
- Direct sales force to oncologists
- Business development to pharma
- Clinical publications and conferences
Customer Segments
- Oncologists (clinical)
- Pharma/Biotech companies (research)
- Academic researchers
Costs
- R&D for platform and assay development
- SG&A including sales and marketing teams
- Lab operations and sequencing reagents
Adaptive Biotechnologies Product Market Fit Analysis
Adaptive Biotechnologies translates the immune system's genetic code into clinical intelligence. Its platform provides ultra-sensitive disease detection for oncologists to personalize treatment and empowers pharmaceutical partners to develop novel therapies faster. This is changing how we diagnose and treat complex diseases like cancer, making medicine more predictive and proactive, ultimately saving lives.
Detecting disease earlier and more accurately than any other technology.
Enabling personalized treatment decisions that improve patient outcomes.
Accelerating the development of next-generation immunotherapies.
Before State
- Imprecise, lagging indicators of disease
- One-size-fits-all treatment decisions
- Reactive responses to patient relapse
- Blind spots in drug development research
After State
- Ultra-sensitive, early disease detection
- Personalized, data-driven therapy choices
- Proactive intervention before relapse
- Accelerated, targeted drug discovery
Negative Impacts
- Delayed detection of recurring cancer
- Unnecessary, toxic overtreatment
- Poor clinical trial outcomes & costs
- Missed opportunities for novel drugs
Positive Outcomes
- Improved patient survival rates & QoL
- Optimized healthcare system resources
- Higher probability of drug approval
- New era of immune-based medicines
Key Metrics
Requirements
- Broad physician adoption and education
- Seamless integration into clinical workflows
- Robust data infrastructure and security
- Strong evidence generation for payers
Why Adaptive Biotechnologies
- Map immune system to decode disease
- Deliver actionable clinical insights
- Partner with pharma to create new drugs
- Make this a new standard of care
Adaptive Biotechnologies Competitive Advantage
- Proprietary platform, largest database
- Regulatory approvals and clearances
- Deep integration with pharma partners
- First-mover in clinical immunosequencing
Proof Points
- FDA clearance for clonoSEQ in 3 cancers
- 100+ peer-reviewed clinical publications
- Partnerships with 90+ pharma companies
- Medicare coverage for multiple indications
Adaptive Biotechnologies Market Positioning
AI-Powered Insights
Powered by leading AI models:
Gemini
- No data acquisition information available
Strategic pillars derived from our vision-focused SWOT analysis
SCALE clonoSEQ to dominate the MRD testing standard of care
EXPAND immune medicine platform for novel drug discovery
DRIVE data network effects to build an immune mapping moat
ACHIEVE cash flow breakeven through disciplined execution
What You Do
- Maps the adaptive immune system to diagnose and treat diseases.
Target Market
- Clinicians and researchers in oncology and autoimmune disease.
Differentiation
- Proprietary immune receptor sequencing and mapping platform.
- Vast, clinically annotated immunomics database for insights.
Revenue Streams
- MRD testing services (clonoSEQ)
- Pharma R&D services (immunoSEQ)
Adaptive Biotechnologies Operations and Technology
AI-Powered Insights
Powered by leading AI models:
Gemini
- No data acquisition information available
Company Operations
- Organizational Structure: Functional structure with two commercial business units: MRD and Immune Medicine.
- Supply Chain: Relies on Illumina for sequencing hardware and key reagents.
- Tech Patents: Extensive patent portfolio covering immunosequencing methods and applications.
- Website: https://www.adaptivebiotech.com/
Adaptive Biotechnologies Competitive Forces
Threat of New Entry
Low: High barriers to entry due to required scale of data, complex proprietary technology, regulatory hurdles (FDA), and clinical adoption.
Supplier Power
Moderate: High dependence on Illumina for sequencing platforms and reagents gives them pricing power, but we are a key customer.
Buyer Power
Moderate: Large pharma partners have significant negotiating power. Hospital systems and payers (CMS) dictate reimbursement terms.
Threat of Substitution
Moderate: Alternative technologies like proteomics, transcriptomics, or improved imaging could emerge for disease monitoring.
Competitive Rivalry
High: Natera is a fierce, well-funded competitor in MRD. Guardant Health and Foundation Medicine also compete in broader oncology testing.
AI Disclosure
This report was created using the Alignment Method—our proprietary process for guiding AI to reveal how it interprets your business and industry. These insights are for informational purposes only and do not constitute financial, legal, tax, or investment advice.
Next Step
Want to see how the Alignment Method could surface unique insights for your business?
About Alignment LLC
Alignment LLC specializes in AI-powered business analysis. Through the Alignment Method, we combine advanced prompting, structured frameworks, and expert oversight to deliver actionable insights that help companies understand how AI sees their data and market position.